Search the Newsreel

AbCellera (ABCL) Soars 64% as Drug Candidate Holds Huge Market Opportunity

AbCellera (ABCL) saw its stock price jump by 64% last week, becoming the top-performing mid-cap stock in the US market, following strong phase 2 clinical trial results for its drug candidate ABCL635 for hot flashes in menopausal women. The drug successfully reduced hot flash …

MLCMF SEC Filings - MILLICOM INTERNATIONAL CELLULAR SA 10-K, 10-Q, 8-K Forms

This page provides a comprehensive resource for MILLICOM INTERNATIONAL CELLULAR SA (Ticker: MLCMF) SEC filings, including 10-K, 10-Q, 8-K forms, and insider trading reports. Each filing is accompanied by expert analysis from Rhea-AI, offering insights into its potential market impact, an AI-generated summary, sentiment …

Omnicell, Inc. $OMCL Shares Acquired by Empowered Funds LLC

Empowered Funds LLC significantly increased its stake in Omnicell, Inc. (NASDAQ:OMCL) by 4,229.9% in the first quarter, now owning 262,043 shares valued at $8.7 million. This comes as other institutional investors have also adjusted their positions in the healthcare technology company. Insider transactions show …

ImmuCell Corporation - Common Stock (ICCC) Stock Price, News, Quote & History

Can AbCellera Biologics (ABCL)’s Vertex Pharmaceuticals Incorporated (VRTX) Deal Turn its TCE Platform Into a Breakthrough?

On July 29, AbCellera Biologics Inc. (NASDAQ:ABCL) and Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) announced a strategic collaboration to research, develop, and commercialize multispecific T-cell engagers (TCEs) for autoimmune diseases. Under the agreement, AbCellera will leverage its proprietary TCE platform to lead discovery, while Vertex will …

Cellebrite (CLBT) Stock Rebounds As ARR Grows But Outlook Cools

Cellebrite DI (NASDAQ:CLBT) Posts Earnings Results, Beats Expectations By $0.06 EPS

Kaplan Fox is Investigating Cellebrite DI Ltd. (NASDAQ: CLBT) for Potential Securities Law Violations

Kaplan Fox & Kilsheimer LLP is investigating potential securities law violations by Cellebrite DI Ltd. (NASDAQ: CLBT). This investigation follows Cellebrite's second-quarter results, which missed ARR projections, a reduction in full-year guidance, and an abrupt CEO change, leading to a significant 29% drop in …

Cellebrite DI Ltd (CLBT) Stock Up 3.1% and Still Undervalued -- GF Score: 84/100

Cellebrite DI Ltd (CLBT) shares rose 3.1% to $11.14 but are still considered undervalued with a GF Value estimate of $16.09, suggesting a 30.8% margin of safety. The stock boasts a strong GF Score of 84/100 due to robust fundamentals and growth potential, despite …

CLBT|Cellebrite DI Ltd|Price:11.110|Chg%:+0.310

Cellectar Biosciences (CLRB): Caligan Partners reports 5.9% ownership stake

Caligan Partners LP and David Johnson have reported a beneficial ownership stake of 5.9% in Cellectar Biosciences (CLRB), amounting to 469,998 shares. This ownership is held through Caligan-managed funds and accounts, with shared voting and dispositive power. The percentage is based on 7,991,812 shares …

ImmuCell Corporation 2026 Q2 - Results - Earnings Call Presentation (NASDAQ:ICCC) 2026-08-14

FuelCell Energy Inc. stock rises Friday, outperforms market

FuelCell Energy Inc. (FCEL) stock rose significantly on Friday, gaining 9.98% to $22.37, despite a generally negative day for the broader market. Both the NASDAQ Composite Index and the Dow Jones Industrial Average experienced declines. The company's stock closed 40.95% below its 52-week high …

Cellebrite DI (NASDAQ:CLBT) Given New $16.00 Price Target at JPMorgan Chase & Co.

JPMorgan Chase & Co. has lowered its price target for Cellebrite DI (NASDAQ:CLBT) from $20.00 to $16.00, while maintaining an "overweight" rating. This new target implies a potential upside of 45.79% from the stock's current price of $10.97. Other analysts have also adjusted their …

Cellectar Biosciences (CLRB) investor discloses 9.99% stake and warrant holdings

SilverArc Capital Management, LLC and Devesh Gandhi have reported a beneficial ownership of 9.99% in Cellectar Biosciences Inc. Class A Common Stock, totaling 851,285 shares. This disclosure, made via a SCHEDULE 13G SEC filing, indicates shared voting and dispositive power over these shares. The …

Kynam Capital (CLDX) group discloses 6.78% Celldex Therapeutics ownership stake

Kynam Capital Management, LP, along with Kynam Capital Management GP, LLC and Yue Tang, has disclosed a beneficial ownership of 6.78% in Celldex Therapeutics, Inc. This ownership translates to shared voting and dispositive power over 5,322,908 shares of Celldex's common stock. The filing, a …

Legal & General Group (FCEL) reports 2.42M FuelCell Energy shares in 13G/A

Legal & General Group Plc and its investment management affiliates reported beneficial ownership of 2,419,645 shares of FuelCell Energy, Inc. common stock, representing 3.6% of the class. This disclosure was made in a SCHEDULE 13G/A filing, indicating shared voting and dispositive power among the …

Cellebrite DI (NASDAQ:CLBT) Sees Unusually-High Trading Volume After Strong Earnings

ImmuCell Q2 2026 slides: revenue gains offset by margin pressure

ImmuCell (NASDAQ:ICCC) reported mixed Q2 2026 results, with product sales up 11.5% to $7.2 million, but gross margin significantly compressed from 43.7% to 33.9%. Despite a tripling of net income to $1.8 million largely due to a $2 million legal settlement, the stock dropped …

ImmuCell Corporation - Common Stock ICCC

ImmuCell Corporation (ICCC) is a biotechnology company focused on veterinary products, particularly for enhancing immune health in livestock. The company's stock recently traded at $10.20, down 6.47%, and has a market cap of $78.93 million. Recent news highlights include Q2 2026 earnings results, increased …

CLBT SHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors of Potential Securities Claims Involving Cellebrite DI Ltd.

SueWallSt has initiated an investigation into potential securities law violations by Cellebrite DI Ltd. (NASDAQ: CLBT) following a significant drop in its share price. The investigation stems from Cellebrite's Q2 2026 revenue falling below analyst expectations and the company subsequently lowering its full-year 2026 …

Cellebrite DI (CLBT) Cuts Guidance And Changes CEO, Is The Stock Now Cheap?

Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million individual investors worldwide. Cellebrite DI (CLBT) has come under fresh scrutiny after its August 13 Q2 2026 earnings report, guidance cut, and CEO transition, with Levi …

T. Rowe Price Associates (CLDX) discloses 6.0% Celldex Therapeutics ownership on Schedule 13G

T. Rowe Price Associates has disclosed a 6.0% beneficial ownership stake in Celldex Therapeutics Inc. (CLDX) through a Schedule 13G filing. The firm reported holding 4,686,187 shares of common stock, with sole voting power over 4,683,226 shares and sole dispositive power over all 4,686,187 …

ImmuCell Q2 Earnings Call Highlights

Key Points Interested in ImmuCell Corporation? Here are five stocks we like better. Strong domestic growth drove results: Second-quarter product sales rose 11.5% year over year to $7.2 million, while net income increased to $1.8 million from $500,000. Domestic sales grew 27.7%, offsetting a …

Earnings call transcript: ImmuCell posts strong Q2 2026 sales growth, shares fall

Turkcell Iletisim Hizmetleri AS Stock 12‑Month Price Target Cut to $8.14, Implies 50% Upside

Turkcell Iletisim Hizmetleri AS (TCELL) has seen its average 12-month price target lowered from $8.23 to $8.01 by 7 analysts, with forecasts ranging from $7.07 to $9.23 per share. This new target implies a potential upside of approximately 48% from its August 13 closing …

Turkcell (NYSE: TKC) Q2 2026: 5G capex surges as margins tighten

Turkcell reported Q2 2026 revenue of TRY 71.8 billion, a 2.5% year-on-year increase under hyperinflation accounting, with net income declining by 5.7% to TRY 5.2 billion. The company experienced tightened margins due to significant 5G investments, including a USD 1.2 billion license, which also …

Needham cuts Cellebrite stock price target on guidance reduction

Needham has lowered its price target for Cellebrite DI Ltd. (NASDAQ:CLBT) to $12.50 from $15.00, while maintaining a Buy rating. This adjustment follows Cellebrite's reduced fiscal 2026 guidance for annual recurring revenue and total revenue, alongside the appointment of Shiven Ramji as the new …

Balyasny Asset Management (CLRB) discloses 9.99% Cellectar stake via stock and warrants

Balyasny Asset Management and affiliated entities have disclosed a 9.99% beneficial ownership stake in Cellectar Biosciences (CLRB) through a Schedule 13G SEC filing. This stake comprises 220,000 common shares and 578,382 shares issuable upon the exercise of warrants, all held under a 9.99% Beneficial …

Millicom International Cellular SA (NASDAQ:TIGO) Receives Consensus Recommendation of "Moderate Buy" from Brokerages

Millicom International Cellular SA (NASDAQ:TIGO) has received a "Moderate Buy" consensus recommendation from brokerages, with an average 12-month price target of $80.82. This follows recent positive earnings results where the company reported $0.97 per share, exceeding estimates. Despite increased institutional investment, an insider recently …

TKC5983608 Bond Coupon Profile — Rate & Payments

This article provides the coupon profile for the TKC5983608 bond issued by Turkcell Iletisim Hizmetleri A.S. It details the current coupon rate of 7.65% and notes the next payment is scheduled for January 25, 2027. The article also highlights features available for researching bond …

AbCellera Biologics Stock 6-Day Winning Spree: Stock Climbs 85%

Does Cellebrite DI’s Lowered 2026 Outlook and New CEO Reset Its AI Narrative (CLBT)?

In August 2026, Cellebrite DI Ltd. reported second-quarter results showing revenue of US$131.14 million and net income of US$6.37 million, while lowering its full-year 2026 revenue guidance to US$555 million–US$561 million and announcing Shiven Ramji's appointment as CEO, succeeding Thomas E. Hogan. The combination …